Alcohol Abuse Clinical Trial
Official title:
Neurobiological Factors Underlying Sex Differences in Risk for Alcohol Abuse
Verified date | August 2023 |
Source | University of Kentucky |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will determine the neural and hormonal mechanisms underlying sex differences in sensitivity to the disinhibiting effects of alcohol in heavy drinkers.
Status | Completed |
Enrollment | 22 |
Est. completion date | May 24, 2023 |
Est. primary completion date | May 24, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 29 Years |
Eligibility | Inclusion Criteria: - heavy drinking - Alcohol Use Disorder Identification Test score above 7 - right-handed - BMI between 19 and 26 - high school education - fluent in English - women must have regular menstrual cycles - not using hormonal contraceptives Exclusion Criteria: - drug use disorder (SCID, DSM-5), other than nicotine or caffeine - meets withdrawal criteria - history of physical or psychiatric disease - contraindication for fMRI - pregnant or breastfeeding - smoking more than 5 cigarettes per day |
Country | Name | City | State |
---|---|---|---|
United States | University Of Kentucky Psychology Research Lab | Lexington | Kentucky |
Lead Sponsor | Collaborator |
---|---|
Mark Fillmore | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Brain Activation During Response Inhibition (BARI) | Brain activation during response inhibition (BARI) will be assessed using blood oxygenation level dependent (BOLD) fMRI during performance of the stop signal task with alcohol compared to to placebo. Values will be determined by the contrast of BOLD activation during successful inhibition trials relative to go trials. | 4 weeks | |
Secondary | Change in Estradiol Levels | Estradiol levels will be measured from blood samples with alcohol compared to to placebo. | 4 weeks | |
Secondary | Change in Progesterone Levels | Progesterone levels will be measured from blood samples with alcohol compared to to placebo. | 4 weeks | |
Secondary | Change in Testosterone Levels | Testosterone levels will be measured from blood samples with alcohol compared to to placebo. | 4 weeks | |
Secondary | Change in Biphasic Alcohol Effects Score | The Biphasic Alcohol Effects Scale (BAES) is a 14-point self-reporting, unipolar adjective rating scale designed to measure both stimulant and sedative effects of alcohol. Scores range from 0-10 for each of the 14 questions. Higher scores indicate increased stimulation or sedation. Scores will be reported with alcohol comparted to placebo. | 4 weeks | |
Secondary | Change in Drug Effects Questionnaire Score | Drug Effects Questionnaire (DEQ) consists of simple, face-valid, visual analog scale (VAS) questions on which people report their subjective states after ingesting a substance. The analog scale of responses ranges from "not at all" to "extremely." Scores are measured in millimeters from the scale origin. Higher scores (longer lengths) indicate greater drug effects. Scores will be reported with alcohol comparted to placebo. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03165942 -
Neuroendocrine Response to Oral Alcohol Administration
|
Phase 1 | |
Recruiting |
NCT05343039 -
Technology Enhanced Adolescent Mental Health (TEAM)
|
N/A | |
Active, not recruiting |
NCT04070521 -
EEG Monitoring in the Emergency Department
|
||
Completed |
NCT03169244 -
Buproprion for Binge Drinking
|
Phase 2 | |
Recruiting |
NCT05246202 -
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
|
N/A | |
Completed |
NCT05036499 -
PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain
|
N/A | |
Recruiting |
NCT04368416 -
Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
|
||
Not yet recruiting |
NCT04557631 -
Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
|
||
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02448134 -
A Community-Based Strategy for Preventing Underage Drinking
|
N/A | |
Completed |
NCT02681406 -
Smartphone Based Continuing Care for Alcohol
|
N/A | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Withdrawn |
NCT01796158 -
Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use
|
N/A | |
Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Withdrawn |
NCT01511679 -
Brain-imaging and Adolescent Neuroscience Consortium
|
N/A | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Withdrawn |
NCT01275391 -
cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT00907309 -
Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use
|
Phase 1/Phase 2 |